Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar Q1 2025 net revenues $170.5M, down 1%; GAAP net income falls to $25.3M

Negative Impact 3 of 5 earnings Written later

Amphastar Pharmaceuticals reported first-quarter 2025 results for the three months ended March 31, 2025, with net revenues of $170.5 million, down 1% from $171.8 million a year earlier. GAAP net income fell to $25.3 million, or $0.51 per diluted share, from $43.2 million, or $0.81 per share, in the prior-year quarter. Lower glucagon and epinephrine sales and higher operating expenses offset growth in BAQSIMI, so shareholders saw lower revenue and profit compared with the prior-year quarter.

Key points

  • Net revenues were $170.5 million, down 1% from $171.8 million; BAQSIMI product revenue rose 177% to $38.4 million.
  • GAAP net income was $25.3 million, or $0.51 per diluted share, versus $43.2 million, or $0.81, a year earlier.
  • Adjusted non-GAAP net income was $36.9 million, or $0.74 per diluted share, versus $55.3 million, or $1.04, in the prior-year quarter.
  • Gross margin was 50.0% versus 52.4% a year earlier; research and development expenses rose to $20.1 million from $17.0 million.

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECMay 7, 2025, 4:23 PM ET
Accession number0001297184-25-000025

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.